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Abstract
The formation of toxic protein aggregates is a common denominator to many neurodegenerative diseases
and aging. Accumulation of toxic, possibly infectious protein aggregates induces a cascade of events, such as
excessive inflammation, the production of reactive oxygen species, apoptosis and neuronal loss. A network of
highly conserved molecular chaperones and of chaperone-related proteases controls the fold-quality of proteins
in the cell. Most molecular chaperones can passively prevent protein aggregation by binding misfolding inter-
mediates. Some molecular chaperones and chaperone-related proteases, such as the proteasome, can also hydro-
lyse ATP to forcefully convert stable harmful protein aggregates into harmless natively refoldable, or
protease-degradable, polypeptides. Molecular chaperones and chaperone-related proteases thus control the
delicate balance between natively folded functional proteins and aggregation-prone misfolded proteins, which
may form during the lifetime and lead to cell death. Abundant data now point at the molecular chaperones and
the proteases as major clearance mechanisms to remove toxic protein aggregates from cells, delaying the onset
and the outcome of protein-misfolding diseases. Therapeutic approaches include treatments and drugs that can
specifically induce and sustain a strong chaperone and protease activity in cells and tissues prone to toxic
protein aggregations.
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The Folding Pathway Leading to Native
and “Alter-Native” States
The polypeptide primary sequence contains all of
the necessary information for it to reach a native
three-dimensional structure, without the apparent
need for external factors (Anfinsen, 1973). During de
novo synthesis, or translocation into the mitochon-
dria, proteins emerge unfolded from the ribosome
or the translocation pores. When exposed to water,
hydrophobic segments tend to spontaneously
collapse into water-excluding hydrophobic cores,
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surrounded by hydrophilic residues (Morgan et al.,
1998). The spontaneous formation of secondary
structures therein may then lead to a discrete native
structure (Fig. 1, reaction 1), which is, in principle,
more stable than the unfolded state. Anatively folded
monomer may already be fully functional, as in the
case of myoglobin. Yet, evolutionally more complex
enzymes may form discrete native oligomers com-
posed of several near-native monomers, as in the
case of the hemoglobin tetramer (Suzuki and Imai,
1998). Although very similar to functional myoglo-
bin, the unassembled nonfunctional hemoglobin
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monomer is in a near-native state, which is, in con-
trast, prone to degradation by proteases. The ability
of folded proteins to alternate between native, near-
native or “alter-native” states (Fig 1, upper path),
demonstrates that within the native folding path-
way, a single polypeptide chain may reach several
distinct native states, separated only by shallow
kinetic barriers (Fig. 1, reaction 2). Thus, to regulate
a given activity, cells may modulate the equilibrium
between an active native state and an inactive “alter-
native” state of a given polypeptide, instead of more
costly modulations of protein amounts by balanc-
ing synthesis with degradation. However, this ener-
getically more favourable level of control necessitates
the presence of fold-controlling factors that can
specifically distinguish between native, “alter-
native” and nonnative states of thousands of differ-
ent proteins in the cell. Experimental data now point
at the molecular chaperones, in particular at Hsp90
and Hsp70, as being such fold-controlling factors
that can regulate transitions between native
monomeric and oligomeric states and thus regulate
the activity of a plethora of native protein functions
in the cell (for a review about Hsp90, see Pratt and
Toft, 2003).
The Misfolding Pathway Leading
to Aggregation
Although the polypeptide primary sequence may
contain all of the necessary information to reach a
native three-dimensional structure (Anfinsen, 1973),
under physiological conditions of temperatures,
molecular crowding and when the concentration of
un/folding intermediates is high, mistakes in the
folding/refolding process may occur, leading to
aggregation (Ellis, 2001). Some native proteins are
intrinsically more stable than others. Destabilizing
mutations, the presence of degradation or secretory
signals, transit-peptides or tags (SsrAor ubiquitin), can
increase the rate of spontaneous unfolding and the
conversion of native proteins into protease-sensitive
Fig. 1. Model for the role of molecular chaperones in protein unfolding. Under physiological conditions (upper path),
an unfolded newly synthetised, or translocated polypeptide may spontaneously fold (1) into a native monomer, and/or
(2) further assemble into an “alter-native” discrete oligomer. ATPase unfolding chaperones can actively deoligomerize
(-2) “alter-native” oligomers into monomers and further unfold (-1) near-native monomers to be translocated across membranes
or degraded. Under stressful conditions (lower path), or because of mutations, a newly synthesized may spontaneously
misfold (3) into a soluble, possibly toxic monomer, which may further assemble (4) into a continuum of small toxic oligomers
that may further condense (5) into less toxic, compact amyloids. Specific organic molecules, may destabilize, and ATPase
chaperones, actively scavenge (-5, -4) compact amyloids and fibbers into looser, albeit more toxic oligomers. ATPase
chaperones may further unfold (-3) and detoxify misfolded monomers into harmless protease products or natively refolded
proteins. The leftward reactions are against entropy and ATP hydrolysis may be needed for the chaperones and proteases
to forcefully unfold stably misfolded or alternatively folded protein structures.
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or translocation-competent polypeptides (Prakash
and Matouschek, 2004).
Conceptually, protein misfolding is to be clearly
distinguished from unfolding and aggregation.
Unfolding is the partial, or global, loss of tertiary
and secondary structures in a protein. Misfolding
addresses possible intramolecular rearrangements
that may take place during synthesis, or following
stress-induced unfolding, within the tertiary and
secondary structures of a given polypeptide, as 
compared to its native structure. The propensity of
a protein to misfold depends on intrinsic properties,
such as the relative amount and distribution of
hydrophobic and charged residues (Chiti et al., 2002),
and on the length of the polypeptide (Mogk et al.,
1999; Uversky, 2002). In contrast, aggregation is a
concentration-dependent, intermolecular process,
whereby already formed misfolded monomers tend
to associate mostly by hydrophobic interactions in
a highly cooperative manner.
Noticeably, a minority of proteins, such as Tau
and α-synuclein in neural cells, Late Embryogene-
sis Abundant (LEA) proteins, and dehydrins in plant
seeds are “natively unfolded” proteins that are
inclined to stay naturally devoid of secondary struc-
tures in the cytoplasm under normal conditions
(Uversky, 2002). In contrast, the remaining majority
of proteins characterized by an average charge-
to-hydrophobicity ratio are highly unstable when
partially unfolded in the cell. Depending on the
degree and duration of an unfolding stress, they tend
to readily acquire nonnative misfolded structures
enriched in β-sheets that gradually aggregate into
larger, more compact and less soluble complexes
(Fig. 1, reactions 3–5). Hence, in the misfolding path-
way, the protein structure is much less controlled by
the primary sequence than in the native folding path-
way. Misfolding intermediates spontaneously accu-
mulate short default cross β-conformations, some
with hydrophobic surfaces, at the expense of more
labile native α-helices (Uversky, 2003). Although pro-
teins in their misfolded state must be thermody-
namically less stable than in their native state, stable
ensembles of misfolded proteins can accumulate and
affect cells because exposed hydrophobic surfaces
must cooperatively associate to escape direct con-
tact with water and thus form highly cohesive aggre-
gates, fibrils, and amyloids. Here, unlike with
discrete native oligomers, aggregates span a wide
range of sizes and morphologies, depending on the
concentration of the misfolded monomers, the pres-
ence of mutations, or on the intensity and duration
of a stress applied (for a review, see Jahn and Rad-
ford, 2005). Compared to native proteins, aggregates
may be detrimental to the cell, as they are devoid of
biological activity in the classical sense. Large aggre-
gates can physically disrupt cells and tissues. They
expose hydrophobic surfaces that can interfere with
other misfolding proteins and with membranes. Dis-
turbance of membrane function is of particular
importance to neurons because minor alterations
causing ion leakage (Lashuel et al., 2002), may have
dramatic consequences on neural activity (for a
review, see Caughey and Lansbury 2003). Moreover,
misfolding protein intermediates may interfere with
the native folding pathway of other proteins in the
cell and induce cross-aggregations (Satyal et al., 2000;
Ben-Zvi and Goloubinoff, 2002; Gidalevitz, et al.,
2006), a proteinaceous infectious behavior, which is
particularly effective in the case of mammalian and
yeast prions (Prusiner, 1989; Jones and Tuite, 2005).
The Cellular Role of Molecular
Chaperones
Molecular chaperones are composed of several
classes of conserved proteins (Table 1) with essential
physiological functions such as assisting the folding
of nascent polypeptides and pulling proteins across
membranes (Neupert and Brunner, 2002; Deuerling
and Bukau, 2004; De Los Rios et al., 2006). In addition,
most molecular chaperones are stressed-induced
proteins (Hsps) that can prevent the aggregation and
facilitate the correct refolding of stress-labile, or
mutation-sensitive proteins (Hartl and Hayer-Hartl,
2002). Some chaperones, in particular the small
Hsps, can also protect membrane from environ-
mental stresses (Torok et al., 1997). By virtue of their
strong buffering on the deleterious effects of mild
aggregation-inducing mutations, the molecular
chaperones serve as capacitors for phenotypic varia-
tions, modulating the pace of molecular evolution
(Queitsch et al., 2002).
The stress-inducible nature of many molecular
chaperones has led to their early classification among
the heat shock proteins (Hsps) according to their
apparent molecular weights in gels: Hsp100, Hsp90,
Hsp70 (Hsp40, Hsp20), Hsp60 (Hsp10), and
Hsp22/27 in eukaryotes (co-chaperones in brack-
ets), corresponding in Escherichia coli to ClpB, HtpG,
DnaK (DnaJ, GrpE), GroEL(GroES), IbpA/B, respec-
tively (Table 1). Various mechanisms by which dif-
ferent individual molecular chaperones may assist
the native folding of proteins have been studied 
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in vivo using mutagenesis and genetic approaches,
and in vitro using biochemical, biophysical and even
physical approaches (Goloubinoff et al., 1989;
Goloubinoff et al., 1999; Ben-Zvi et al., 2004; De Los
Rios et al., 2006). Different chaperones display mutu-
ally nonexclusive properties. Some “binding” chap-
erones, such as Hsp90, Hsp70, Hsp60, Hsp40, and
Hsp22/27, can provide adhesive surfaces which,
upon interaction with partially denatured polypep-
tides, can passively reduce the degree of aggrega-
tion (Chatellier et al., 2000; Mogk et al., 1999).
“Folding” chaperones, such as Hsp100, Hsp70, and
Hsp60 (possibly also Hsp90), are involved in the
ATP-dependent native refolding of artificially dena-
tured polypeptides (Table 1) (Goloubinoff et al., 1989;
Goloubinoff et al., 1999; for a review, see Ben-Zvi and
Goloubinoff, 2001). Misfolded polypeptides may be
transferred from “binding” to “unfolding” chaper-
ones, thereby allowing optimal cooperation in the
recovery of native proteins by the various chaper-
one systems (Veinger et al., 1998; Ben-Zvi and
Goloubinoff, 2001; Mogk et al., 2003).
The remarkable ability of the disaggregating chap-
erones Hsp70 and Hsp100 to recognize, bind mis-
folded and aggregated proteins, and forcefully
convert the latter into natively refoldable polypep-
tides demonstrates that chaperones can act as true
enzymes. Like enzymes, they accelerate the conver-
sion of stable, high-affinity misfolded substrates into
more stable, low-affinity natively refolded products.
Some chaperones can use the energy of ATP-hydrol-
ysis to overcome the high kinetic barrier between the
two states (Fig 1, reactions -5, -4, -3) (Goloubinoff 
et al., 1999; Ben-Zvi et al., 2004). Understanding the
mechanisms by which the chaperone and protease
network can specifically recognize toxic misfolded
protein conformers in the cell and convert them into
nontoxic, natively refolded or degraded polypep-
tides is central to the comprehension of protein-
misfolding neuropathologies and for conceiving
possible therapies.
The Role of the Molecular Chaperones
in Neurodegenerative Diseases
The accumulation in and outside neurons, of pro-
tein aggregates compacted into amyloid plaques,
fibrils or neurofibrillary tangles, which is accompa-
nied by an excessive inflammatory response, oxida-
tive stress, and cell death, are common characteristics
of most neurodegenerative diseases, such as
Alzheimer’s, Parkinson’s, Huntington’s diseases,
amyotrophic lateral sclerosis, and prion
encephalopathies (Dobson, 1999; Muchowski and
Wacker, 2005). Age is the main risk factor in most
protein-conformation neurodegenerative diseases.
Moreover, several protein conformational disorders
may develop in the same aging patients, suggesting
a general failure of the protein fold-quality control
in aging tissues (Hamilton and Bowser 2004; Forman
et al., 2002; Soti and Csermely, 2003).
There is now a large body of evidence indicating
that the molecular chaperones and chaperone-
controlled proteases, such as the proteasome, belong
to a cellular network that can prevent and reduce
the formation of toxic aggregates and possibly 
Table 1
Major Classes of Molecular Chaperones In Mammals: Cellular Location 
and Central Functions in Protein Misfolding Diseases
Signalling   
Passive & prevention 
Cellular prevention Active of apoptosis
Name location ATPase of aggregation unfolding (overexpression)
Eukaryotes Prokaryotes Eukaryotes
Hsp100 Clp B MT + − + ?
Hsp90 HtpG Cyt, ER, MT + + ? +
Hsp70, Hsc70 DnaK Cyt, ER, MT + + + +
Hsp40 DnaJ Cyt, ER, MT − (catalyzes + − +
ATPase
in Hsp70)
Hsp60 GroEL MT + + + −
Hsp22/27 IbpA, IbpB Cyt, ER, MT − + − +
Cyt, cytoplasm; ER, endoplasmic reticulum; MT, mitochondria; Hsp, heat-shock protein.
JMN06_0017_Goloubinoff  12/4/06  2:51 PM  Page 252
Hsp Chaperones and Conformational Diseases 253
Journal of Molecular Neuroscience Volume 30, 2006
eliminate already formed toxic protein aggregates
in neurodegenerative diseases (Muchowski et al.,
2000; Barral et al., 2004; Klucken et al., 2004; for a
review, see Muchowski and Wacker, 2005).
Most reports thus far correlate between the pres-
ence of one, or a selective choice of molecular chap-
erones (typically Hsp70, Hsp40, Hsp90, and/or
Hsp27) with reduced amounts of a given neurotoxic
aggregate and, more rarely, with the clearance of 
pre-existing aggregates. The general picture is as 
follows.
1. Overexpression of one, or better, of the whole chap-
erone and protease network strongly correlates with
a diminution of protein aggregation, toxicity, inflam-
mation, and neuronal loss. Overexpression of Hsp70
inhibits inflammation, the production of reactive
oxygen species (ROS) and consequent apoptosis.
2. Underexpression of members of the chaperone or the
protease network, as in aging, by RNA inhibition,
mutations or by using specific inhibitors, strongly
increases toxic protein aggregation, inflammation and
cell death.
3. Molecular chaperones act ubiquitously. No particu-
lar chaperone can be assigned to the relieving or curing
of a specific protein conformation disorder. All pro-
tein-misfolding diseases, among them neurodegen-
erative ones, favourably respond to chaperone
overexpression and negatively respond to chaperone
underexpression, mutation or inhibition.
4. Seldom, imbalanced expression between the various
chaperones (typically Hsp70 and co-chaperones) can
lead to deleterious effects.
Below, we have summarized some milestone
observations about the central role of molecular
chaperones as factors that control the fold-quality of
proteins in the cell, in the particular context of neuro-
degenerative diseases.
Alzheimer disease (AD) is characterized by the
extra-cellular accumulation of Aβ-amyloids and the
intracellular accumulation of neurofibrillary tangles
of the otherwise natively unfolded Tau protein (for
a review, see LaFerla and Oddo, 2005). Direct inter-
actions among Hsp70, Hsp90, and Tau have been
observed in COS-1 cells expressing human Tau.
Induction of Hsp70 and Hsp90 by mild poisoning
with geldanamycin, correlated with increased Tau
solubility, whereas Hsp70 and Hsp90 suppression
by RNA interference significantly decreased Tau 
solubility (Dou et al., 2003).
Parkinson’s disease (PD) is characterized by intra-
cellular and membrane-interfering aggregates of the
presynaptic neuronal protein: α-synuclein (Tofaris
et al., 2005). Whereas expression of α-synuclein in
Drosophila flies leads to neuronal loss, its co-expres-
sion with human Hsp70 significantly decreased neu-
ronal loss (Auluck et al., 2002). This strongly suggests
that human Hsp70 can reduce neurotoxicity by
actively unfolding α-synuclein aggregates. In mam-
malian cells, expression of Hsp27 has protective
effects against α-synuclein and huntingtin-induced
cell-death (Zourlidou et al., 2004), probably by
passively sequestering the toxic interactive surfaces
of the aggregates.
Familial amyotrophic lateral sclerosis is a neuro-
degenerative disease associated with mutation-
induced aggregation of Cu/Zn superoxide dismutase
(SOD-1) (Selverstone Valentine et al., 2005). Hsp70
co-expression with aggregation-prone SOD-1 can sig-
nificantly lower SOD-1 aggregation and prolong cell
viability (Bruening et al., 1999). A direct association
of Hsp70, Hsp40, and αB-crystallin with mutant 
SOD-1 was demonstrated by coimmunoprecipitation.
In human cell lines, a direct association between
human mutant SOD-1 and Hsp70, Hsp40 and 
α−crystallin has been shown (Shinder et al., 2001).
Neuronal loss from various polyglutamine dis-
eases results from mutations in different proteins
that generate in-frame expansions of glutamine
repeats (polyQ tracks). In a cellular model for Hunt-
ington’s disease, human neuroblastoma cells
expressing huntingtin (with extended polyQ tracts),
and the co-expression of both Hsp70 and Hsp40 or
of only Hsp40, significantly lowered huntingtin
aggregation and cell death (Wyttenbach et al., 2000).
Hsp40 is the central co-chaperone of Hsp70 that can
bind aggregates by itself, as well as catalyze Hsp70
binding onto the aggregate (Table 1) (Laufen et al.,
1999; Ben-Zvi et al., 2004). Thus, excess Hsp40 may
sequester toxic conformers. Similarly, the co-expres-
sion in mouse of the yeast chaperone Hsp104 with
the first 171 residues of a huntingtin mutant resulted
in a decrease of aggregate formation and in a 20%
increased survival as compared to mice expressing
only the mutant huntingtin (Vacher et al., 2005).
Hsp27 expression was also shown to significantly
inhibit polyQ-induced cell death, although without
reducing the formation of detectable aggregates
(Wyttenbach et al., 2002). As with excess of Hsp40,
passive binding of toxic hydrophobic surfaces by
Hsp27 may suffice to prevent the onset of an apop-
totic signal. Moreover, indicating that the protec-
tive mechanism mediated by Hsp27 differs from
active aggregate-scavenging by Hsp70/Hsp40,
some endogenous Hsp70 and Hsp40, but not Hsp27,
were found sequestered into the insoluble protein
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inclusions. In this case, alongside with neutralizing
toxic soluble aggregates in the cytosol and passively
preventing the formation of hydrophobic pore-
forming neurotoxic aggregates (Lashuel et al., 2002),
small Hsps may also stabilize aggregate-damaged
membranes (Torok et al., 2001).
In a cellular model of spinocerebellar ataxias,
Hsc70 and two Hsp40 isoforms were colocalized
with polyQ aggregates of mutant ataxin-3 fragments.
Coexpression of human Hsp40 suppressed ataxin-3
aggregates, whereas coexpression of Hsp70 or Hsp27
remained ineffective (Chai et al., 1999). Expression
of another human Hsp40, Hdj-2, could also suppress
aggregation of mutant androgen receptor and of
ataxin-1 (Cummings et al., 1998; Stenoien et al., 1999).
In a system modeling spinal and bulbar muscular
atrophy—cultured neuronal cells expressing trun-
cated androgen receptor protein with an expanded
polyQ tract—only the combination of overexpressed
Hsp70 and Hsp40 can reduce the formation of aggre-
gates and prevent apoptosis, whereas over express-
ing Hsp40 alone has no effect (Kobayashi et al., 2000).
Prion related-diseases are particular in that the
toxic protein aggregates can also propagate and
induce neighbouring cells to produce toxic protein
aggregates (Prusiner, 1989) and undergo apoptosis.
Prion disease in mammals results from the confor-
mational conversion of a native, α−helix rich PrPc
protein, into an aggregation-prone, β-sheet-enriched,
infectious PrPsc species. In yeast, several nonpatho-
logical prions have been identified, from proteins
such as Sup35, Ure2, and Rnq1 (Jones and Tuite,
2005). Overproduction of the ATPase chaperone
Hsp104 (the yeast homologue of bacterial ClpB), or
of a cytosolic Hsp70 (Ssb) can transiently cure the
[PSI+] yeast prion phenotype of the Sup35 protein,
suggesting that disaggregating molecular chaper-
ones can act upon prion particles (Chernoff et al.,
1995). The role of Hsp70 chaperones in prion curing
is, however, to be considered cautiously as over-
production of another member of the Hsp70 family,
Ssa1, resulted in the propagation of the yeast prion
(Chernoff et al., 1999).
Possible Detrimental Effects
of Chaperone Activity
Strong evidence points at abnormally exposed
hydrophobic surfaces as being the pathogenic and
infectious parts of the protein aggregates (Bieschke
et al., 2004). Simply because of differences in the
surface/volume ratio, the specific pathogenicity and
infectiousness of a given misfolded protein is expected
to be the highest when it is in a least-compacted
monomeric state, and the lowest when it is assem-
bled within large compact aggregates (Fig. 1, reac-
tions -5 and -4). Eukaryotic cells have developed a
dynein- and microtubule-dependent transport
mechanism, named the aggresome, which can
actively concentrate small toxic aggregates into
denser, presumably less harmful inclusion bodies
(Kopito, 2000). This raises the possibility of a conflict
between aggregate-detoxification by aggresome-
mediated compaction (Fig. 1, reaction 6) vs detoxi-
fication by chaperone-mediated unfolding of
aggregates (Fig. 1, reactions -5, -4, -3), the latter being
able to transiently generate smaller but more toxic
forms from larger less toxic amyloids. Increased
infectiousness has been demonstrated in vitro with
sonication treatments which, mimicking scavenging
chaperones, artificially converted large noninfectious
PrPsc particles into smaller infectious ones (Bieschke
et al., 2004). In yeast, although overexpression of
the scavenging chaperone Hsp104 can virtually cure
the [PSI+] prion phenotype, deletion of the hsp104
gene inhibits [PSI+] propagation (Chernoff et al.,
1995). This confirms that under specific conditions,
such as during “unprotected” scavenging by Hsp104
or Hsp70, some toxic aggregates may form and
prions may propagate from larger inactive forms
of aggregates.
Although there is overwhelming evidence that
Hsp70 overexpression, prior to or during early neuro-
toxic protein aggregation, has powerful neuropro-
tective and anti-apoptotic effects (Magrane et al.,
2004), occasional reports indicate that Hsp70 over-
expression may accelerate cell death, as in the case
of tumor necrosis factor (TNF)-treated Cos-1 cells
(Ran et al., 2004) or of lentiviral-mediated over-
expression of Hsp70, alongside α-synuclein in rat
brains (P. Aebischer, personal communication). Inter-
estingly, Hsp70 has a unique molecular mechanism
whereby the energy of ATP is used to recruit random
movements of the chaperone molecule to apply a
local unfolding force on the misfolded polypeptide
susbstrate (Ben-Zvi et al., 2004; De Los Rios et al.,
2006). Thus, individual Hsp70 molecules fully suf-
fice to breakdown large aggregated particles into
smaller ones. However, the cooperativity of at least
three Hsp70 molecules, independently bound to the
same misfolded polypeptide, is necessary to com-
plete the unfolding of the latter into a natively refold-
able species (Ben-Zvi et al., 2004). This implies that
a mild but insufficient expression of Hsp70 in the
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cell, as in the neuronal tissues of aging mammals,
may suffice to initiate partial breakdown of some
least-harmful amyloids into fragmented, more toxic
particles. However, at this stage, the reaction could
become stalled for lack of sufficient Hsp70 molecules
to cooperate in the final conversion of most toxic
species into harmless natively refoldable, or pro-
tease-degradable, species (De Los Rios et al., 2006).
There is no obvious Hsp104 homolog in human that
can assist Hsp70-mediated protein disaggregation.
However, neural cells may still recruit binding chap-
erones, such as Hsp27 (Patel et al., 2005), to reduce
the transient toxicity of newly formed hydrophobic
surfaces during amyloid scavenging by Hsp70.
The Role of the Proteasome
in Neurodegenerative Diseases
In agreement with the observations that chaperones
and the proteasome carry complementing protective
cellular mechanisms against protein-conformational
diseases (Fig. 1, reaction 7), immunostaining has
revealed the presence of ubiquitin, proteasomal sub-
units and of Hsp70 in neuronal nuclei of cells with
amyloids of several diseases, including AD, Parkin-
son’s disease, and prion diseases (Adori et al., 2005).
Inhibition of the proteasome activity with MG-132
in mouse cell lines and primary neurons, or inhibi-
tion of calpain or other cytosolic proteases, favors
the cytosolic accumulation of PrPsc and prion patho-
genesis (Wang et al., 2005c). Noticeably, the endo-
plasmic reticulum Hsp70 (BIP) controls the folding
of PrP, and an anomalous, prolonged association
between BIP and mutant PrP32 inhibits subsequent
proteasome-mediated degradation of the misfolded
PrP32, leading to prion disease (Jin et al., 2000). Sim-
ilarly, aggregated α-synuclein strongly associates and
inhibits proteasome activity, suggesting that protea-
some-mediated degradation of misfolded α-synuclein
is a central cytoprotective mechanism in Parkinson’s
disease. Indeed, rats treated with proteasome
inhibitors developed typical Parkinson pathologies
(Nomoto and Nagai, 2005). In human neuroblastoma
cells expressing the α-synuclein mutant A53T, 
co-expression of Parkin, a E3-ubiquitin-ligase, alle-
viates the α-synuclein toxicity (Petrucelli et al., 2002).
Similarly, in human neuroglioma cells, co-expression
of CHIP, an Hsp70 co-chaperone with an E3-ubiqui-
tin-ligase activity acting as a molecular switch between
proteasomal and lysosomal degradation pathways,
decreases the levels of aggregated α-synuclein (Shin
et al., 2005). In COS cells, CHIP co-expression with a
truncated polyQ-rich human huntingtin suppressed
both huntingtin aggregation and toxicity (Miller et
al., 2005). In mouse neuroblastoma cell lines, over-
expression of another E3 ubiquitin ligase, Dorfin,
provided protection from neurotoxic mutant SOD-1
(Niwa et al., 2002). Because E3 ubiquitin-ligases have
a significantly more restricted spectrum of substrates
than the molecular chaperones and proteases, it is
possible that targeted degradation of specific neuro-
toxic aggregates can be achieved by overexpressing
specific E3 ubiquitin-ligases.
Aging
A general age-dependent decrease in the ability
to express Hsps and antioxidant enzymes under
stress is observed in all multicellular organisms, from
mammals, nematodes, and insects, to plants (Mor-
rison et al., 2005; Starnes et al., 2005). Failure of aging
humans to induce and maintain a molecular heat-
shock response consequent to an abiotic, or a cellu-
lar stress, strongly correlates with the onset of
protein-conformation disorders, in particular of
neurodegenerative diseases (Soti and Csermely,
2003). Figure 2A shows a scheme of the various age-
dependent processes, correlating the decline of chap-
erone and proteasome activity in the cell, with
expected levels of toxic aggregates and of inflam-
mation leading to fatal neuronal loss. Because the
stability of the native state is primarily an intrinsic
property of each protein, the rate of spontaneous
protein unfolding, leading to misfolding and aggre-
gation, is expected to be rather constant during
lifetime, with a possible mild increase later in life due to
cumulative mutations and damages from polluting
chemicals such as heavy metals (Basha et al., 2005),
ionizing radiations, ozone, tobacco smoke, and
environmental stresses (ultraviolet light, tempe-
rature variations etc.) (Manton et al., 2004; Landrigan
et al., 2005). Early in life, however, the chaperone
and protease network is optimally inducible and can
effectively prevent the steady formation of small
toxic aggregates and, furthermore, actively unfold,
reactivate, or eliminate all the misfolded species that
may form in young unstressed cells. Later in life,
when the chaperone and protease network becomes
gradually deficient (Heydari et al., 2000), toxic
aggregates may accumulate, but partial protection
may still be achieved by active secretion, lysosomal
degradation, or aggresome-mediated sequestration
of the most toxic species into dense fibbers and
compact amyloids (Kopito, 2000). Yet, above a critical
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threshold of aggregation, the various cell defences
may become overpowered, inducing an inflammatory
response with the release of ROS, leading to apoptosis
(Soti and Csermely, 2003).
The Proteasome and Aging
The activity of the proteasome has been reported
to decrease with age in cell cultures and in vivo
(for a review, see Gaczynska et al., 2001). Decline of
proteasome activity has been reported in several
aged human tissues, such as lens, muscle, lympho-
cytes, and epidermis, as well as in senescing human
primary cultures. Asimilar tendency was observed
in aging tissues of other mammals (for a review see
Chondrogianni and Gonos 2005). Free ROS produced
by chronic inflammation can cause cumulative
damages to cellular macromolecules and in par-
ticular lipids and proteins, and seems to contribute
to senescence and aging, age-related disorders, and
neuromuscular degenerative diseases. The accu-
mulation of oxidized proteins has been reported
in many aging and models of protein-misfolding
diseases. In young individuals, mildly oxidized
and aggregated proteins are rapidly degraded by
the proteasome. As in the case of molecular chap-
erones, the specificity of the proteasome could
depend on the extent of misfolding in oxidized pro-
teins. The 20S proteasome may directly bind and
degrade such mildly damaged proteins, without
needing the ubiquitin targeting. Severely oxidized,
aggregated, and crosslinked proteins, however, are
less efficient substrates for degradation and may
stall the proteasome during aging and in many
age-related conformational disorders (Ferrington
et al., 2005; Davies and Shringarpure, 2005). During
cellular aging and inflammatory degenerative
diseases, the combination between the steady
increase of protein damage from ROS and the
steady decrease in proteasome expression and
activity may result in the accumulation of toxic
protein species, leading to cell death (for a review,
see Ciechanover, 2006).
The artificial triggering of a heat-shock response
in neural cells during the onset of neurodegenera-
tive diseases, or during aging, is expected to improve
cellular levels of chaperones and proteases (Fig. 2B,
arrow) and consequently delay the accumulation of
toxic protein aggregates. To lower neuronal loss and
increase life quality and expectancy, therapeutic
approaches may include the use of Hsps inducers,
in turn preventing and actively reverting protein
aggregation. Complementing therapeutic approaches
may include the use of direct inhibitors of protein
aggregation and of anti-oxidants able to directly
quench ROS damages, and inhibit ROS-mediated
apoptotic signals.
Therapeutic Approaches: Aggregate-
Interfering Compounds
A number of small organic molecules have been
shown to retard and, more rarely, to reverse the
formation of toxic protein aggregates in various in
vivo and in vitro model systems. Compounds with
high affinity for aggregated proteins, such as the
Fig. 2. Scheme of the age-dependent processes leading
to fatal neuronal loss. Early in life, the chaperone and pro-
tease networks are optimally inducible and active. They
effectively prevent the accumulation of toxic protein aggre-
gates. The rate of spontaneous misfolding and aggregation
is constant, with a possible mild increase later in life because
of cumulative mutations and stress-induced damages. Later
in life, the chaperone and protease network become defi-
cient and toxic aggregates accumulate. Some aggregates
are partially sequestered by the aggresome, others induce
inflammation and reactive oxygen species, leading to fatal
neuronal loss. (A) Early failure of the chaperone and pro-
tease network lead to early death by neurodegeneration.
(B) Effect of improved activity (arrow) of the chaperone and
protease network, by Hsp-inducing drugs or treatments,
delay in fatal neuronal loss and increase in life expectancy.
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amphiphilic fluorescent dye Bis-ANS, can inhibit the
in vitro aggregation of PrPsc (Cordeiro et al., 2004).
Similarly, congo red, a dye used to detect amyloid
deposits in histological slices, can inhibit α-synu-
clein formation in vitro and in cell cultures (Heiser
et al., 2000). Feeding congo red or cystamine to
Drosophila flies expressing a polypeptide with an
expanded polyQ-repeat suppressed degeneration of
photoreceptors and neurons (Apostol et al., 2003).
In a transgenic mouse model for Huntington dis-
ease, the transglutaminase inhibitor cystamine,
increased survival and improved motor function
(Dedeoglu et al., 2002). Rifampicin applied to rat
cells inhibited the aggregation and neurotoxicity of
synthetic Amyloid-β peptides (Tomiyama et al.,
1996). Interestingly, rifampicin can strongly bind to
α-synuclein monomers, inhibit fibrillation, and pos-
sibly mediate the solubilization of preformed 
α-synuclein fibbers in vitro, suggesting a direct inter-
ference of rifampicin with toxic α-synuclein aggre-
gates in the cell (Li et al., 2004b). Similarly, curcumin
treatments abrogated retention of myelin protein
zero aggregates into the endoplamic reticulum (ER)
and reduced aggregate-induced apoptosis (Khajavi
et al., 2005), as well as the formation of Amyloid-β
oligomers and fibrils (Yang et al., 2005).
The various beneficial effects of small organic
compounds, such as Bis-ANS, Thyoflavin-T, cur-
cumin, and congo Red, on aggregate reduction in
cells raises the question of their precise mechanism
of action. In a cell-free system, interfering com-
pounds often bind strongly to stable aggregates,
although without causing solubilization. Therefore,
similar high-affinity binding of such compounds
in the cell may not necessarily drive to the solubi-
lization of compact amyloids. Consequently,
candidate therapeutic molecules should first be
tested for their potential ability to induce the
expression of molecular chaperones and proteases.
This should allow one to distinguish between direct
aggregate-interfering compounds and Hsp-inducing
compounds acting indirectly on aggregates by
way of increasing the aggregate- scavenging activity
of the cell.
Hsp-Inducing Treatments
The demonstrated ability of stress-inducible chap-
erones and proteases to prevent the accumulation of
toxic protein aggregates in the cell implies that drugs
capable of increasing Hsp expression, without
increasing the misfolding propensity of sensitive
proteins, may delay the onset of, and possibly cure,
protein-misfolding and age-related diseases.
Caloric Restriction and Hormonal Treatments
In mammalian cells, glucose starvation induces
the massive accumulation of a specific subset of ER-
located molecular chaperones, such as Grp78 and
Grp94 (for a review, see Lee, 2001). Grp78 overex-
pression provides protection of cells against induced
apoptosis (Liu et al., 1997; Reddy et al., 1999). Inter-
estingly, high levels of both chaperones in the brain
of young rats correlate with higher resistance to
seizures, compared to older rats expressing less
Grp78 and Grp94 (Little et al., 1996). Mild hypo-
glycemia may thus suffice to induce ER chaperones,
which in turn may increase the resistance of cells
to various stresses, age-dependent protein aggre-
gations in the ER, and aggregate-induced apoptosis.
Noticeably, caloric restriction is the most effective
anti-aging treatment in mammals (for a review, see
Kirkwood and Shanley, 2005). Caloric restriction,
while increasing levels of molecular chaperones,
also prevents age-related declines of glycolytic
enzymes in the neural retina of aging rats (Li et al.,
2004a). Interestingly, treatments with estrogens and
androgens, in addition to glucose regulating hor-
mones, also increased Hsp70 levels in human
neurons and induced resistance to toxic intracel-
lular amyloids (Zhang et al., 2004). It is therefore
possible that the anti-aging effect of mild caloric
restriction and of some hormonal treatments affect-
ing glucose uptake are mediated, in part, by way
of induced Hsp-expression with anti-inflamma-
tory, anti-apoptotic, and anti-protein aggregation
activities.
Heat-Shock
Since antiquity, repeated mild heat-shock treat-
ments, in the form of hot baths and saunas, are
considered to have age-retarding and relieving
effects on age-related chronic diseases. It is now
well established in all organisms that repeated mild
thermal treatments can prime the accumulation of
heat-inducible proteins, most of which being
transcription factors, molecular chaperones and
proteases (Kregel, 2002). Indeed, mild heat-shock
treatments are the simplest way to induce Hsps in
the cell and gain protection, both against direct
damages from subsequent harsher environmental
stresses, and against indirect damages from 
ROS-induced inflammation leading to cell death
(Beere, 2004).
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The Role of Fever
Hippocrates (460–377 B.C.) is quoted to have said:
“Give me the power to create a fever and I shall cure
every illness.” During inflammation, homeothermal
organisms develop high fever, during which high
levels of Hsps accumulate everywhere, including in
the central nervous system, in correlation with the
onset of various healing processes (for a review, see
Moseley, 1998). As in the case of the response to heat-
shock, the ability of animals to induce high fever and
Hsps decreases with age (Soti and Csermely, 2003;
Macario and Conway de Macario, 2005). Elevated
levels of heat-shock proteins are nonetheless often
observed associated to various forms of amyloids
and protein aggregates in degenerated neural tissues
of deceased aged patients, which is not necessarily
in contradiction with the general observation that
Hsp-inducibility late in life is mediocre: aging tissues
exposed to toxic aggregates may have first attempted
to recruit some Hsps, but having failed to recruit
enough of them, succumb to programmed cell death.
Noticeably, repeated mild heat-shock treatments can
partially restore Hsp-inducibility in aging flies
(Hercus et al., 2003) and increase post-heat stress
survival of organisms as different as bacteria, yeast,
plants, nematodes, and mammals (Rattan, 2004). This
suggests that repeated mild heat-treatments in aging
humans with protein conformational diseases may
restore some ability to induce and accumulate
molecular chaperones and proteases, and thus
prevent toxic aggregation in neurones, delaying the
onset of cell death.
Aging mammals, humans in particular, also show
deregulated inflammatory responses (Bruunsgaard
et al., 2001). For example, aging rats become increasingly
defective at developing high fever (Plata-Salaman
et al., 1998). In aging humans and patients suffering
from chronic inflammatory diseases, a positive corre-
lation exists between serum levels of Hsp70 and
various inflammatory markers, such as TNF-α, 
C-reactive protein, and fibrinogen. This suggests
that Hsp70 is directly linked to the inflammatory
response, as well as to the immune and autoimmune
responses (Njemini et al., 2004). For example, in
rheumatoid arthritis and other spondyloarthro-
pathies, with a pathogenesis attributed, in part, to
the interaction between genetic and environmental
factors, synovial cells continuously over-express
Hsp70 or Hsc70 (Vargas-Alarcon et al., 2002). Hsc70
may be upregulated as a result of the high activity
of these cells in several respects, including antigen
processing and presentation (Schick et al., 2004). The
most recent hypothesis implies a special interaction
between HLA-DR chains from rheumatoid arthritis
and members of the Hsp70s, which may affect antigen
processing and antigen presentation (Roth et al.,
2002). Indeed, the loading of the DR molecules with
T-cell epitopes and presentation apparently depends
on Hsc70 levels. Moreover, Hsp70 and Hsp60 have
been shown to protect against cell death by inter-
fering with the mitochondrial apoptosis pathway
(Saleh et al., 2000; Zamostiano et al., 1999). Yet, when
applied on the external surface of cells, Hsp70 may
have a pro-inflammatory role (Asea et al., 2000; Asea
et al., 2002). This is exemplified in the case of the
acute respiratory distress syndrome (ARDS), which
is an inflammatory response in the lungs resulting
from severe damage to alveolar cells, culminating
in necrosis and fatal apoptosis, especially in aging
patients. Sepsis-induced ARDS in rats has been
shown to correlate with the specific failure of Hsp70
to be expressed in alveolar tissues (Weiss et al., 2000).
In a rat model of sepsis-induced ARDS, adenovirus-
mediated transient expression of Hsp70 in the lungs,
effectively prevented apoptosis and lung failure. It
dramatically improved survival (Weiss et al., 2002).
These effects are partly due to a mechanism whereby
Hsp70 directly impairs proteasomal degradation of
IkBα (Weiss Y., personal communication). Interest-
ingly, during the viral infection that caused the Severe
Acute Respiratory Syndrome (SARS) outbreak, the
death toll from an ARDS was lower than 10% in
patients younger than 35 yr, but reached 66% in
patients older than 75 years (Ghani et al., 2005). It is
tempting to speculate that the diminished ability of
aging SARS patients to induce Hsp70 accumulation
in septic lungs could partly account for the strong
age-dependent death toll in SARS patients.
Hsp-Inducing Drugs by Partial Poisoning
Some successful attempts to reduce neurotoxic
protein aggregations have been obtained with a class
of chemicals that can induce a heat-shock response
at physiological temperature, as a result of partial
poisoning by inhibition of protein synthesis, of chap-
erone-mediated protein un-folding, or of the protein
degradation machinery. Chinese hamster ovary
cells treated with intermediate concentrations of
puromycin (20 mg/mL) showed a 1.5-fold increase
in the synthesis of Hsps, including Hsp70. However,
higher concentrations of puromycin (e.g., 100
mg/mL) resulted in an inhibition of Hsp synthesis
(Lee and Dewey, 1987). Similarly, subsaturating
concentrations of specific inhibitors of Hsp90
JMN06_0017_Goloubinoff  12/4/06  2:52 PM  Page 258
Hsp Chaperones and Conformational Diseases 259
Journal of Molecular Neuroscience Volume 30, 2006
(geldanamycin and radicicol) (Hay et al., 2004) or of
the proteasome (MG-132 and lactacystin) were also
shown to induce a strong heat-shock response, leading
to Hsp accumulation and some anti-aggregation
effects (Holmberg et al., 2000). Thus, subinhibitory
amounts of geldanamycin and radicicol in mice
cells increased the sodium dodecyl sulfate (SDS)-
solubility of polyQ-aggregates and of α-synuclein
in human and Drosophila cells (McLean et al., 2004).
In a rat model for Parkinson’s disease, exposure to
the proteasome inhibitor 6-hydroxyl dopamine
showed a protective effect on dopaminergic cell
death. Co-treatment of lactacystin and MG-132
significantly prevented the nigral degeneration and
appearance of α-synuclein and ubiquitin-positive
inclusions in substantia nigra (Inden et al., 2005).
However, Hsp induction by poisoning is expectedly
prone to severe adverse effects. Most inhibitors are
hydrophobic and cannot be simply delivered to neural
cells at precise low Hsp-inducing concentrations while
being safely kept below excessive concentrations
capable of inducing apoptosis. There is a significant
risk that treatment with a mild excess of Hsp90 or
proteasome inhibitors may induce apoptosis, as they
do in anti-cancer protocols (Setsuie et al., 2005).
Anti-Inflammatory and Hsp-Inducing Drugs
As alternatives to partial poisoning drugs and
problematic thermotherapies, other drugs can speci-
fically induce a heat-shock-like response at physio-
logical temperature, without apparent cell poisoning.
Cyclopentenone prostaglandins (PGA2 and D12-
PGJ2) were among the first compounds to show a
strong activation of Hsp70 synthesis in HeLa cells
(Ohno et al., 1988). More recently, treatment of human
cells with the antiproliferative prostaglandin A1 acti-
vated the heat-shock transcription factor (Hsf1) and
consequently the accumulation of Hsp70 and Hsp90
(Amici et al., 1992). Whereas a moderate inflamma-
tory response, in part mediated by high fewer
following infection (as in septic lungs) or by protein
aggregation in brain tissues, may contribute to the
general induction and accumulation of anti-apoptotic
heat-shock proteins, an excessive deregulated inflam-
matory response can lead to cell death and tissue
degeneration (Beere and Green, 2001; Craft et al.,2005).
This suggests possible therapies for neurodegene-
rative diseases with anti-inflammatory drugs. Yet,
because anti-inflammatory drugs may also decrease
fever, they should be chosen according to their 
ability to maintain Hsp accumulation despite their
ability to decrease fever (Marchetti and Abbracchio,
2005). This is the case for some famous commercial
remedies, such as the nonsteroidal anti-inflammatory
drug (NSAIDs) ibuprofen (Wang et al., 2005b), and
acetyl-salicylic acid (aspirin), which can both reduce
fever and inflammation while keeping a strong heat-
shock like response at physiological temperatures, in
terms of nuclear relocalization of Heat-shock factor-1
and of massive production molecular chaperones such
as Hsp70 and Hsp90, not only in animals (Jurivich et
al., 1992; Westerheide and Morimoto, 2005), but also
in plants (Saidi et al., 2005). The ability of some
NSAIDs to maintain high Hsp levels while decreas-
ing unwanted effects of excessive inflammation could
account for their significant healing effects on inflam-
mation-induced neuronal loss (Marchetti and
Abbracchio, 2005). For example, in HeLa cells,
ibuprofen induction of Hsp70 correlates with a
reduced aggregation of a polyalanine expansion
mutant of poly(A)-binding protein, a hallmark of
oculopharyngeal muscular dystrophy (Wang et al.,
2005b). Epidemiological data have shown that con-
stant treatment with NSAIDs reduces the risk of
Parkinson’s diseases by 45%, compared to patients
taking NSAIDs on a nonregular basis (Schiess, 2003).
Similarly, prolonged use of NSAIDs was shown to
reduce the risk of developing AD and delay the onset
of the disease. Studies with Flurbiprofen or ibupro-
fen in AD transgenic mice have shown that the effects
of these NSAIDs on Aβ deposition are reached at
plasma levels similar to those achieved in humans
at therapeutic dosage (for a review, see Gasparini
et al., 2004).
Other Hsp-Inducing Drugs
Recently, very old and new compounds were
added to the list of least poisonous heat-shock
response inducers, such as Bimoclomol (Vigh et al.,
1997), Arimoclomol (Kieran et al., 2004), Arachidonic
acid, Curcumin, Resveratrol (the French paradox,
Delmas et al., 2005), Geranylgeranylacetone (Susuki
et al., 2005) and Celastrol (Westerheide et al., 2004).
Very low concentrations of these compounds can
strongly induce Hsf-1 expression and heat-shock pro-
tein accumulation in eukaryotic cells, likely by way
of modulating membrane fluidity or by interfering
with the heat-shock signalling pathway (Jurivich
et al., 1992; Vigh et al., 1997; Hargitai et al., 2003). The
antiulcer drug Geranylgeranylacetone strongly
induced Hsp70 in various tissues without apparent
adverse effects and caused a marked inhibition of
apoptosis and of oxydative damages related to
ischemic heart reperfusion, renal failure and liver
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transplantation (Suzuki et al., 2005). Moreover, oral
uptake of Geranylgeranylacetone leads to neuro-
protection against cerebral infarction in rats and
alleviates polyglutamine-mediated motor neuron
disease (Katsuno et al., 2005; Uchida et al., 2006). The
membrane fluidizer Arimoclomol can significantly
delay the progression of amyotrophic lateral sclero-
sis in transgenic mice overexpressing mutant human
SOD-1 (Kieran et al., 2004). Micromolar amounts of
Celastrol, a quinone triterpene from the Chinese phar-
macopoeia, also strongly activates the heat shock
transcription factor Hsf1 and chaperone accumula-
tion in plants (Saidi and Goloubinoff, personal com-
munication) and in human cells, with kinetics similar
to heat stress (Westerheide et al., 2004). Celastrol is
also effective at reversing the abnormal cellular local-
ization of full-length mutant Huntingtin observed in
striatal cells (Wang et al., 2005a).
Hsp-Inducing Peptides
Whereas external application of short insoluble
peptide aggregates, such as β-amyloid, can induce
neural cell death in vitro, soluble neurotrophic pep-
tides, such as the vasoactive intestinal peptide (VIP)
and the activity-dependent neurotrophic factor
(ADNF), can protect neural cells from β-amyloid
induced apoptosis (for a review, see Gozes et al., 2005).
Hence, VIP-stimulated astrocytes can secrete short
peptides, such as ADNF, which, already at femtomolar
concentrations, can increase the levels of mitochon-
drial Hsp60 while protecting neurons from death
associated with a broad range of toxins, including
those related to Alzheimer’s disease (Zamostiano et al.,
1999). It is therefore possible that by way of inducing
mitochondrial chaperonins, natural neuropeptides
may arrest apoptosis, leading to the development of
possible peptide-based drugs against protein-
misfolding diseases (Gozes and Brenneman, 1996).
Conclusions
Molecular chaperones are fold-controlling factors
(see Table 1) that can specifically recognize misfolded
or alternatively folded protein structures in the cell.
Chaperones can single out and remove atypical,
potentially toxic, and infectious protein structures
by various cellular programs:
1. Prevention: binding chaperones can bind misfolded
proteins and prevent them from forming large aggre-
gates.
2. Passive unfolding: aggregate-interfering compounds
can destabilize aggregated proteins.
3. Passive protection: binding chaperones can bind
hydrophobic surfaces of already formed aggregates
and protect membranes and proteins from toxic
interactions.
4. Active unfolding: ATPase chaperones can forcefully
unfold misfolded and aggregated proteins and allow
their native refolding into nontoxic functional pro-
teins (see Table 1).
5. Sequestration: the aggresome can actively sequester
by compaction toxic misfolded species into inclusion
bodies.
6. Secretion: toxic aggregates such as Aβ−amyloids or
PrPsc can be secreted outside the cell.
7. Controlled degradation: chaperone-gated proteases
degrade and recycle non-recoverable damaged
proteins (see Fig 1).
In aging cells, or during abiotic stress or pathogen
attack, the chaperone and protease network may
become overloaded because of massive protein
damage, deficient responsiveness, and insufficient
Hsp accumulation, or because of mutations in sub-
strate proteins or in the chaperones (Fig 2). Several
therapeutic approaches were discussed here that can
potentially improve neurone responsiveness to toxic
protein aggregation or to heat- and oxidative stresses,
thereby increasing the cellular levels of Hsps. Com-
binations of treatments such as caloric restriction,
mild heat-shocks, peptides, and drugs capable of
increasing chaperone and protease levels without
overloading or poisoning the cell, and without
increasing the amount of protein aggregates in the
cell, are likely to improve cell survival to protein
misfolding and reduce neuronal loss. In addition to
treating various neurodegenerative diseases, Hsp-
inducing treatments, possibly in combination with
dietary antioxidants (for a review, see Cui et al., 2004),
may also relieve other protein misfolding and inflam-
matory diseases such as cystic fibrosis (Gelman and
Kopito, 2002), diabetes (Hayden et al., 2005), and, in
general, aging (for a review, see Macario and Conway
de Macario, 2005).
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